{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:54:25Z","timestamp":1790679265533,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00431-009-0937-9","type":"journal-article","created":{"date-parts":[[2009,2,25]],"date-time":"2009-02-25T08:05:36Z","timestamp":1235549136000},"page":"1355-1363","source":"Crossref","is-referenced-by-count":42,"title":["Fabry disease in children and the effects of enzyme replacement treatment"],"prefix":"10.1007","volume":"168","author":[{"given":"Guillem","family":"Pintos-Morell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,26]]},"reference":[{"key":"937_CR1","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105:2812\u20132817","journal-title":"Proc Natl Acad Sci U S A"},{"key":"937_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"937_CR3","first-page":"155","volume-title":"Fabry Disease: Perspectives from 5\u00a0Years of FOS","author":"M Beck","year":"2006","unstructured":"Beck M (2006) Demographics of FOS: the Fabry outcomes survey. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry Disease: Perspectives from 5\u00a0Years of FOS. Oxford PharmaGenesis, Oxford, UK, pp 155\u2013161"},{"key":"937_CR4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M Beck","year":"2004","unstructured":"Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838\u2013844","journal-title":"Eur J Clin Invest"},{"key":"937_CR5","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(04)16254-5","volume":"363","author":"OA Bodamer","year":"2004","unstructured":"Bodamer OA, Ratschmann R, Paschke E et al (2004) Recurrent acroparaesthesia during febrile infections. Lancet 363:1698","journal-title":"Lancet"},{"key":"937_CR6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM et al (1967) Enzymatic defect in Fabry\u2019s disease: ceramidetrihexosidase deficiency. N Engl J Med 276:1163\u20131167","journal-title":"N Engl J Med"},{"key":"937_CR7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of \u03b1-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122\u2013138","journal-title":"Medicine"},{"key":"937_CR8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","volume":"147","author":"MA Cabrera-Salazar","year":"2005","unstructured":"Cabrera-Salazar MA, O\u2019rourke E, Charria-Ortiz G et al (2005) Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr 147:102\u2013105","journal-title":"J Pediatr"},{"key":"937_CR9","first-page":"5","volume":"9","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS (1994) The brief pain inventory, a measure of cancer pain and its impact. Qual Life Newsl 9:5\u20136","journal-title":"Qual Life Newsl"},{"key":"937_CR10","first-page":"149","volume":"83","author":"RJ Desnick","year":"1973","unstructured":"Desnick RJ, Raman MK, Bendel RP et al (1973) Prenatal diagnosis of glycosphingo-lipidoses: Sandhoff\u2019s (SD) and Fabry\u2019s diseases (FD). J Pediatr 83:149","journal-title":"J Pediatr"},{"key":"937_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/08035320600618759","volume":"95","author":"WB Dobyns","year":"2006","unstructured":"Dobyns WB (2006) The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. Acta Paediatr Suppl 95:11\u201315","journal-title":"Acta Paediatr Suppl"},{"key":"937_CR12","first-page":"7","volume":"34","author":"M Elleder","year":"1998","unstructured":"Elleder M, Poupetova H, Kozich V (1998) Fetal pathology in Fabry\u2019s disease and mucopolysaccharidosis type I. Ceskoslov Patol 34:7\u201312","journal-title":"Ceskoslov Patol"},{"key":"937_CR13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184\u2013192","journal-title":"J Inherit Metab Dis"},{"key":"937_CR14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"937_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"937_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmg.20.4.309","volume":"20","author":"N Gadoth","year":"1983","unstructured":"Gadoth N, Sandbank U (1983) Involvement of dorsal root ganglia in Fabry\u2019s disease. J Med Genet 20:309\u2013312","journal-title":"J Med Genet"},{"key":"937_CR17","unstructured":"Fabrazyme\u00ae (agalsidase beta) for intravenous infusion [Prescribing Information]. Boston, MA:Genzyme; 2006"},{"key":"937_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","volume":"3","author":"DP Germain","year":"2002","unstructured":"Germain DP, Avan P, Chassaing A et al (2002) Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 3:10","journal-title":"BMC Med Genet"},{"key":"937_CR19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"937_CR20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold KF, Pastores GM, Botteman MF et al (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317\u2013327","journal-title":"Qual Life Res"},{"key":"937_CR21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00868342","volume":"241","author":"RP Grewal","year":"1994","unstructured":"Grewal RP (1994) Stroke in Fabry\u2019s disease. J Neurol 241:153\u2013156","journal-title":"J Neurol"},{"key":"937_CR22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"MC Gubler","year":"1978","unstructured":"Gubler MC, Lenoir G, Grunfeld JP et al (1978) Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease. Kidney Int 13:223\u2013235","journal-title":"Kidney Int"},{"key":"937_CR23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","volume":"84","author":"MJ Hilz","year":"2000","unstructured":"Hilz MJ, Stemper B, Kolodny EH (2000) Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 84:361\u2013365","journal-title":"Pain"},{"key":"937_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, de Garcia LA, Mehta A et al (2005) Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42:247\u2013252","journal-title":"J Med Genet"},{"key":"937_CR25","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A et al (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5:1447\u20131453","journal-title":"Clin Gastroenterol Hepatol"},{"key":"937_CR26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550\u2013555","journal-title":"Pediatr Res"},{"key":"937_CR27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 94:153\u2013158","journal-title":"Heart"},{"key":"937_CR28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/SPC.0b013e3282eeb45f","volume":"1","author":"TS Jensen","year":"2007","unstructured":"Jensen TS, Finnerup NB (2007) Management of neuropathic pain. Curr Opin Support Palliat Care 1:126\u2013131","journal-title":"Curr Opin Support Palliat Care"},{"key":"937_CR29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","volume":"40","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Baehner F, Whybra C et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40:1668\u20131674","journal-title":"J Am Coll Cardiol"},{"key":"937_CR30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","volume":"130","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Linhart A, Baehner F et al (2008) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367\u2013373","journal-title":"Int J Cardiol"},{"key":"937_CR31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00392-002-0848-5","volume":"91","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Wiethoff CM, Perrot A et al (2002) The heart in Anderson Fabry disease. Z Kardiol 91:786\u2013795","journal-title":"Z Kardiol"},{"key":"937_CR32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","volume":"97","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Wiethoff CM, Whybra C et al (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463\u2013469","journal-title":"Acta Paediatr"},{"key":"937_CR33","first-page":"615","volume":"142","author":"B Kelly","year":"2006","unstructured":"Kelly B, Kelly E (2006) Angiokeratoma corporis diffusum in a patient with no recognizable enzyme abnormalities. Arch Dermatol 142:615\u2013618","journal-title":"Arch Dermatol"},{"key":"937_CR34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/08870449708406744","volume":"12","author":"JM Landgraf","year":"1997","unstructured":"Landgraf JM, Abetz LN (1997) Functional status and well-being of children representing three cultural groups: initial self-report using CHQ-CF87. Psychol Health 12:839\u2013854","journal-title":"Psychol Health"},{"key":"937_CR35","volume-title":"The CHQ User\u2019s Manual","author":"JM Landgraf","year":"1999","unstructured":"Landgraf JM, Abetz LN (1999) The CHQ User\u2019s Manual. HealthAct, Boston, MA"},{"key":"937_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","volume":"17","author":"DA Laney","year":"2008","unstructured":"Laney DA, Fernhoff PM (2008) Diagnosis of Fabry disease via analysis of family history. J Genet Couns 17:79\u201383","journal-title":"J Genet Couns"},{"key":"937_CR37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0923-1811(98)00032-2","volume":"18","author":"L-M Lao","year":"1998","unstructured":"Lao L-M, Kumakiri M, Mima H et al (1998) The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 18:109\u2013117","journal-title":"J Dermatol Sci"},{"key":"937_CR38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K et al (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305\u2013313","journal-title":"Glycobiology"},{"key":"937_CR39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","volume":"93","author":"A Linhart","year":"2007","unstructured":"Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93:528\u2013535","journal-title":"Heart"},{"key":"937_CR40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","volume":"17","author":"DW Loring","year":"2007","unstructured":"Loring DW, Marino S, Meador KJ (2007) Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 17:413\u2013425","journal-title":"Neuropsychol Rev"},{"key":"937_CR41","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1016\/S0960-9822(99)80151-1","volume":"9","author":"MF Lyon","year":"1999","unstructured":"Lyon MF (1999) X-chromosome inactivation. Curr Biol 9:R235\u2013R237","journal-title":"Curr Biol"},{"key":"937_CR42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","volume":"429","author":"J MacDermot","year":"2001","unstructured":"MacDermot J, MacDermot KD (2001) Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 429:121\u2013125","journal-title":"Eur J Pharmacol"},{"key":"937_CR43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769\u2013775","journal-title":"J Med Genet"},{"key":"937_CR44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750\u2013760","journal-title":"J Med Genet"},{"key":"937_CR45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08035320600618809","volume":"95","author":"EM Maier","year":"2006","unstructured":"Maier EM, Osterrieder S, Whybra C et al (2006) Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 95:30\u201338","journal-title":"Acta Paediatr Suppl"},{"issue":"1\u20132","key":"937_CR46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymgme.2008.07.002","volume":"95","author":"A Mehta","year":"2008","unstructured":"Mehta A, Beck M, Kampmann C et al (2008) Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab 95(1\u20132):114\u2013115","journal-title":"Mol Genet Metab"},{"key":"937_CR47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE et al (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254","journal-title":"JAMA"},{"key":"937_CR48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1015009210639","volume":"11","author":"AH Miners","year":"2002","unstructured":"Miners AH, Holmes A, Sherr L et al (2002) Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res 11:127\u2013133","journal-title":"Qual Life Res"},{"key":"937_CR49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","volume":"40","author":"P Mitsias","year":"1996","unstructured":"Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry\u2019s disease. Ann Neurol 40:8\u201317","journal-title":"Ann Neurol"},{"key":"937_CR50","first-page":"491","volume":"75","author":"SH Morgan","year":"1990","unstructured":"Morgan SH, Rudge P, Smith SJ et al (1990) The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)\u2014investigation of symptomatic and presymptomatic patients. Q J Med 75:491\u2013507","journal-title":"Q J Med"},{"key":"937_CR51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00415-007-0575-y","volume":"254","author":"A Palla","year":"2007","unstructured":"Palla A, Hegemann S, Widmer U et al (2007) Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol 254:1433\u20131442","journal-title":"J Neurol"},{"key":"937_CR52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1695-4033(02)77891-0","volume":"57","author":"G Pintos-Morell","year":"2002","unstructured":"Pintos-Morell G (2002) Fabry\u2019s disease: diagnosis in the pediatric age group. An Esp Pediatr 57:45\u201350","journal-title":"An Esp Pediatr"},{"key":"937_CR53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0002-9378(90)90410-9","volume":"162","author":"S Popli","year":"1990","unstructured":"Popli S, Leehey DJ, Molnar ZV et al (1990) Demonstration of Fabry\u2019s disease deposits in placenta. Am J Obstet Gynecol 162:464\u2013465","journal-title":"Am J Obstet Gynecol"},{"key":"937_CR54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","volume":"96","author":"U Ramaswami","year":"2007","unstructured":"Ramaswami U, Wendt S, Pintos-Morell G et al (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96:122\u2013127","journal-title":"Acta Paediatr"},{"key":"937_CR55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86\u201392","journal-title":"Acta Paediatr"},{"key":"937_CR56","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/0091270007305299","volume":"47","author":"M Ries","year":"2007","unstructured":"Ries M, Clarke JT, Whybra C et al (2007) Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J Clin Pharmacol 47:1222\u20131230","journal-title":"J Clin Pharmacol"},{"key":"937_CR57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","volume":"118","author":"M Ries","year":"2006","unstructured":"Ries M, Clarke JT, Whybra C et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924\u2013932","journal-title":"Pediatrics"},{"key":"937_CR58","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","volume":"115","author":"M Ries","year":"2005","unstructured":"Ries M, Gupta S, Moore DF et al (2005) Pediatric Fabry disease. Pediatrics 115:e344\u2013e355","journal-title":"Pediatrics"},{"key":"937_CR59","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","volume":"162","author":"M Ries","year":"2003","unstructured":"Ries M, Ramaswami U, Parini R et al (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162:767\u2013772","journal-title":"Eur J Pediatr"},{"key":"937_CR60","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2165\/00003495-200767180-00005","volume":"67","author":"M Rohrbach","year":"2007","unstructured":"Rohrbach M, Clarke JT (2007) Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 67:2697\u20132716","journal-title":"Drugs"},{"key":"937_CR61","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","volume":"366","author":"A Rolfs","year":"2005","unstructured":"Rolfs A, Bottcher T, Zschiesche M et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794\u20131796","journal-title":"Lancet"},{"key":"937_CR62","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HAI et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"937_CR63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","volume":"97","author":"R Schiffmann","year":"2000","unstructured":"Schiffmann R, Murray GJ, Treco D et al (2000) Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97:365\u2013370","journal-title":"Proc Natl Acad Sci U S A"},{"key":"937_CR64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M et al (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345\u2013354","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"937_CR65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/A:1012423924648","volume":"24","author":"A Sessa","year":"2001","unstructured":"Sessa A, Meroni M, Battini G et al (2001) Renal pathological changes in Fabry disease. J Inherit Metab Dis 24(Suppl 2):66\u201370","journal-title":"J Inherit Metab Dis"},{"key":"937_CR66","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/archopht.1979.01020010327008","volume":"97","author":"NA Sher","year":"1979","unstructured":"Sher NA, Letson RD, Desnick RJ (1979) The ocular manifestations in Fabry\u2019s disease. Arch Ophthalmol 97:671\u2013676","journal-title":"Arch Ophthalmol"},{"key":"937_CR67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"937_CR68","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C Tondel","year":"2008","unstructured":"Tondel C, Bostad L, Hirth A et al (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767\u2013776","journal-title":"Am J Kidney Dis"},{"key":"937_CR69","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/01.CIR.94.11.2850","volume":"94","author":"H Tsuji","year":"1996","unstructured":"Tsuji H, Larson MG, Venditti FJ Jr et al (1996) Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 94:2850\u20132855","journal-title":"Circulation"},{"key":"937_CR70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1447-0756.1985.tb00045.x","volume":"11","author":"O Tsutsumi","year":"1985","unstructured":"Tsutsumi O, Sato M, Sato K et al (1985) Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry\u2019s disease. Asia Oceania J Obstet Gynaecol 11:39\u201345","journal-title":"Asia Oceania J Obstet Gynaecol"},{"key":"937_CR71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","volume":"94","author":"AC Vedder","year":"2008","unstructured":"Vedder AC, Breunig F, Donker-Koopman WE et al (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94:319\u2013325","journal-title":"Mol Genet Metab"},{"key":"937_CR72","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","volume":"29","author":"AC Vedder","year":"2006","unstructured":"Vedder AC, Strijland A, Weerman MA et al (2006) Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29:106\u2013111","journal-title":"J Inherit Metab Dis"},{"key":"937_CR73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J et al (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34\u201345","journal-title":"Genet Med"},{"key":"937_CR74","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","volume":"26","author":"F Weidemann","year":"2005","unstructured":"Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221\u20131227","journal-title":"Eur Heart J"},{"key":"937_CR75","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","volume":"24","author":"C Whybra","year":"2001","unstructured":"Whybra C, Kampmann C, Willers I et al (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24:715\u2013724","journal-title":"J Inherit Metab Dis"},{"key":"937_CR76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"key":"937_CR77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","volume":"152","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152:563\u2013570","journal-title":"J Pediatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-009-0937-9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T14:22:02Z","timestamp":1554646922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-009-0937-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,26]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1007\/s00431-009-0937-9","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,26]]}}}